Keerthana Chandrasekar, Shruthi Jaya Saju, Brisha Hana Zechariah, Jenny Ann John, Sadagoban GK, Arun KP
Keerthana Chandrasekar1, Shruthi Jaya Saju2, Brisha Hana Zechariah2, Jenny Ann John2, Sadagoban GK3, Arun KP4*
1Resident, Department of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, Tamil Nadu, India.
2Department of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, Tamil Nadu, India.
3Lecturer, Department of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, Tamil Nadu, India.
4Assistant Professor, Department of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, Tamil Nadu, India.
Volume - 14,
Issue - 3,
Year - 2021
Background: Antibiotics are potent drugs which are usually used in the treatment of bacterial infections. Aminoglycosides are powerful, broad spectrum antibiotics that exhibits both gram positive and gram-negative coverage and are often used for treatment of bacterial infections in the pediatric patients. Gentamicin and Amikacin are broad spectrum aminoglycoside antibiotics with bactericidal activity and is widely used in the treatment of bacillary infections in infants and children. Clinical effects of gentamicin-related toxicity such as ototoxicity, nephrotoxicity is well known. The incorrect use of aminoglycosides has deleterious effects such as of nephrotoxicity and ototoxicity and can result in the development of resistant pathogens. Therefore, drug utilization evaluation of aminoglycosides can significantly improve their usage. Methods: This study is a retrospective pilot study carried out in a secondary care public hospital, Ooty to understand the Aminoglycoside usage in the pediatric population. A total of 133 cases were collected with aminoglycoside usage during the period of one year from January 2018 to December 2018. The data was collected in the structurally designed data collection form which included patient demographic data such as name, age, gender, body weight, treatment plan including drug, dose, duration, frequency and route of administration, length of hospitalization along with laboratory data such as, microbiological culture sensitivity and renal function test. Results: Among 133 cases, the aminoglycoside commonly prescribed was gentamicin (100) and amikacin (34) which constitutes for 74.6 and 25.4 percentages respectively. The Defined Daily Dose of Gentamicin and Amikacin was calculated and compared with WHO DDD value which was found to be comparable. The DDD per patient and DDD per 1000 patients were calculated respectively to understand the drug utilization pattern of aminoglycosides. The study findings suggested that Aminoglycosides are widely used in Infants and Children and was commonly prescribed for Lower Respiratory Tract Infections and Upper Respiratory Tract Infections, followed by Fever, Viral Fever, Febrile Seizures, Tonsillitis, Acute Gastro Enteritis, Adenoiditis and Urinary Tract Infections. Once daily was more commonly prescribed followed by Twice daily followed by combination therapy. Among the 100 cases of gentamicin prescribed, a total of 18 prescriptions were found to be stopped earlier with 1 day (n=10) or 2 days (n=08). Among the total 39 cases of renal function test done, the patients (n=11) prescribed with Amikacin constitutes about 32.4% and the patients (n=29) prescribed with gentamicin constitutes around 29% respectively. Conclusion: The study findings concluded that Gentamicin and Amikacin usage was appropriate in pediatric population with reference to the DDD values.
Cite this article:
Keerthana Chandrasekar, Shruthi Jaya Saju, Brisha Hana Zechariah, Jenny Ann John, Sadagoban GK, Arun KP. Drug Utilization Evaluation of Aminoglycosides, Gentamicin and Amikacin: A Retrospective study in pediatric patients at secondary care public hospital. Research J. Pharm. and Tech 2021; 14(3):1247-1250. doi: 10.5958/0974-360X.2021.00221.3
1. Maheshwari P, Varunrohith N, Shanmugarajan TS, Shanmugasundaram P. A Prospective Study of Prescribing Patterns of Antibiotics in Post-Operative Patients of Surgery Department. Research Journal of Pharmacy and Technology. 2016; 9(6): 691-3.
2. Ramalingam AJ. History of Antibiotics and Evolution of Resistance. Research Journal of Pharmacy and Technology. 2015 Dec 1; 8(12): 1719.
3. Gupta A. Plazomicin: A step toward next generation aminoglycosides. Review. Asian Journal of Research in Pharmaceutical Sciences. 2017 Sep 25; 7(3): 173-80.
4. Krause, Kevin M et al. “Aminoglycosides: An Overview.” Cold Spring Harbor perspectives in medicine vol. 6,6 a027029. 1 Jun. 2016, doi:10.1101/cshperspect.a027029
5. Hughes, Kaitlin M et al. “Comparison of Amikacin Pharmacokinetics in Neonates Following Implementation of a New Dosage Protocol.” The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG vol. 22,1 (2017): 33-40. doi:10.5863/1551-6776-22.1.33
6. McWilliam SJ, Antoine DJ, Smyth RL, Pirmohamed M. Aminoglycoside-induced nephrotoxicity in children. Pediatric Nephrology. 2017 Nov 1; 32(11): 2015-25.
7. Vakulenko, Sergei B, and Shahriar Mobashery. “Versatility of aminoglycosides and prospects for their future.” Clinical microbiology reviews vol. 16,3 (2003): 430-50. doi:10.1128/cmr.16.3.430-450.2003
8. Takahashi Y, Igarashi M. Destination of aminoglycoside antibiotics in the ‘Post-Antibiotic Era’. The Journal of Antibiotics. 2018 Jan; 71(1): 4-14.
9. Becker B, Cooper MA. Aminoglycoside antibiotics in the 21st century. ACS chemical biology. 2012 Nov 9; 8(1): 105-15.
10. Bhagat PH, Bartlett AH, Nash CB. Evaluation of Extended-Interval Aminoglycoside Dosing (EIAD) in Pediatric Patients. InOpen Forum Infectious Diseases 2016 Dec 1 (Vol. 3, No. suppl_1). Oxford University Press
11. Boralkar SM, Bauskar MR, Khairnar AS. Drug Utilization 90% in General Intensive Care Unit. Research Journal of Pharmacy and Technology. 2011; 4(8): 1201-3.
12. Sisay M, Mengistu G, Molla B, Amare F, Gabriel T. Evaluation of rational drug use based on World Health Organization core drug use indicators in selected public hospitals of eastern Ethiopia: a cross sectional study. BMC Health Services Research. 2017 Dec; 17(1): 161.
13. Management Sciences for Health (MSH), managing drug supply. 1997, 2nd edition, (revised and expanded), Kumarian Press, West Hart Ford, Conn, USA
14. Laing RO, Hogerzeil HV. Ten recommendations to improve use of medicines in developing countries. Health Policy Plan. 2001; 16(1): 13–20.
15. 15.Drug administration and control authority (DACA). Training modules on operation and management of special pharmacies, Birnanenaselam printing enterprise, Ethiopia, 2003. Available at: www.medpages.co.za/sf/ index.php?page=organisationandorgcode=282339. Accessed 10 Jun 2016
16. Porter G, Grills N. Medication misuse in India: a major public health issue in India. Journal of Public Health. 2015 Jun 8; 38(2): e150-7
17. Calikoglu EO, Koycegiz E, Kosan Z, Aras A. Rational drug use and prescribing behavior of family physicians in Erzurum, Turkey. Nigerian Journal of Clinical Practice. 2019 May 1; 22(5): 626.
18. Drug utilization study in OPD of a tertiary care hospital in a rural area of Jalna, Maharashtra, India by using WHO prescribing indicators.
19. Khairnar A, Jamdade S. Prospective Cross-Sectional Observational Study on Evaluation of Drug Utilization 90% Study in Cardiovascular Diseases. Research Journal of Pharmacy and Technology. 2014 Sep 1; 7(9): 5.
20. Jeyanthi T, Subramanian P, Kumaravel P. A comparative analysis of antibacterial activity of withania somnifera root extract with commercial antibiotics. Asian J. Pharm. Res. 2013 Apr; 3(2): 98-102.
21. Alinejad S, Yousefichaijan P, Rezagholizamenjany M, Rafie Y, Kahbazi M, Arjmand A. Nephrotoxic effect of gentamicin and amikacin in neonates with infection. Nephro-Urology Monthly. 2018 Mar;10(2).
22. Gallardo-Godoy A, Muldoon C, Becker B, Elliott AG, Lash LH, Huang JX, et al. Activity and Predicted Nephrotoxicity of Synthetic Antibiotics Based on Polymyxin B. J Med Chem. 2016; 59(3): 1068-77.
23. Khan MY, Roy M, Ahmad M, Ahmad MI, Aziz I. A Review-Acute Respiratory Infections-the Forgotten Killer of Children. Asian Journal of Research in Pharmaceutical Science. 2015;5(1):49-54.
24. Saranya S, Anuradha R. Potential of Carica papaya against Gentamicin Induced Nephrotoxic Rats. Research journal of Pharmacology and Pharmacodynamics. 2012; 4(1): 17.
25. Kashyap S, Sao M, Sharma H, Yadav AP, Kori ML. Nephroprotective Effect of Luteolin against Gentamicin-induced Nephrooxicity in Albino Rats. Research Journal of Pharmaceutical Dosage Forms and Technology. 2019 Sep 30; 11(3): 181-5.
26. Yow MD. An overview of pediatric experience with amikacin. The American Journal of Medicine. 1977 Jun 1;62(6):954-8.
27. Saddi V, Preddy J, Dalton S, Connors J, Patterson S. Variation in Gentamicin Dosing and Monitoring in Pediatric Units across New South Wales. Pediatric Quality and Safety. 2017 Mar;2(2).
28. Nitin M, Ifthekar S. Nephroprotective activity of Vigna mungo (Linn.) Hepper on gentamicin-induced renal damage in albino rats. Research journal of Pharmacology and Pharmacodynamics. 2012 Sep 1; 4(5): 5.
29. O’Sullivan ME, Perez A, Lin R, Sajjadi A, Ricci AJ, Cheng AG. Towards the prevention of aminoglycoside-related hearing loss. Frontiers in Cellular Neuroscience. 2017 Oct 18; 11: 325
30. Namazi S, Sagheb MM, Hashempour MM. Usage pattern and serum level measurement of amikacin in the internal medicine ward of the largest referral hospital in the south of Iran: a pharmacoepidemiological study. Iranian Journal of Medical Sciences. 2016 May; 41(3): 191.
31. McCracken Jr GH. Arninoglycoside toxicity in infants and children.